Khushboo
The corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus type 2 (SARS-CoV-2), belongs to a class of
emerging and re-emerging diseases, which was first identified and reported in Wuhan, China, during December 2019. The analysis of its genetic
sequences suggested it to be similar to SARS viruses, a β-coronavirus. The studies associated to the epidemiology and virology of the disease
suggested that the transmission of SARS-CoV-2 mainly occurs from a symptomatic or infected person to others through a close contact with
the respiratory droplets or by having a contact with the SARS-CoV-2 adhering with the objects and surfaces. The time between the exposure of a
healthy person to the SARS-CoV-2 and the appearance of the symptoms called as incubation period ranges from 5-14 days. During CoVID19, the
orrence of fever, dry cough and tiredness are the most common symptoms. The less commonly occurring symptoms:include aches and pains, chest
pain, conjunctivitis, diarrhea, headache, difficulty in breathing or short breaths, loss of taste, smell, rashes on skin, Sore throat, The most serious
symptoms include difficulty in breathing or shortness of breaths, pressure or pain in chest region, and loss of speech or movement. The diagnostics
to detect the presence an individual with CoVID involves ELISA based tests and RT PCR. There is no specific treatment available to eradicate
CoVID19. As the world is facing coronavirus pandemic, there is a steep rise in degree of fear, worry and concern in the population with CoVID19
mainly the health care provider, infants, pregnant ladies and the older adults as well as those receiving treatment in hospitals. This disease has been
recently reported to be associated with the development of psychosomatic disorders including depression. This paper presents an overview of the
current status of depression developing in the SARS CoV2 infected people, and strategies to combat the CoVID19 pandemic.